Printer Friendly

ENDOTRONICS, INC. RECEIVES U.S. PATENT ON SCALABLE OXYCELL CELL CULTURE TECHNOLOGY

 ENDOTRONICS, INC. RECEIVES U.S. PATENT ON SCALABLE OXYCELL
 CELL CULTURE TECHNOLOGY
 MINNEAPOLIS, Feb. 5 /PRNewswire/ -- Endotronics, Inc. (NASDAQ: ENDO) announced today that it received a patent from the U.S. Patent Office for its new proprietary cell culture biorecator, OXYCELL(TM). Patents are currently pending in Europe and Japan.
 Richard E. Sakowicz, president and chief operating officer of Endotronics, said, "We believe the OXYCELL technology will provide a key technology advantage for Endotronics. We intend to incorporate the OXYCELL technology into our next generation of systems from research scale to very large production scale for therapeutic bioproducts. We believe the OXYCELL bioreactor technology will overcome scalability limitations of all cell culture technologies by allowing optimal direct delivery of oxygen to the cell mass. This allows the bioreactor to support an increased number of viable cells per unit volume which results in higher system productivity and lower operating cost. The OXYCELL bioreactor technology is currently being used in our newest research scale instrument, the ACUMOUSE(TM). The ACUMOUSE is a cost- effective alternative to using ascites (mice) as a source of monoclonal antibodies for research into treatments for cancer, AIDS, hepatitis and other diseases."
 Endotronics, Inc., headquartered in Minneapolis, is dedicated to providing cell processing products and services to meet the emerging needs of human health care and biotechnology markets worldwide. The company is a recognized industry leader in hollow fiber cell culture instrumentation with more than 675 instruments installed worldwide.
 -0- 2/5/92
 /CONTACT: Yvonne L. Marschner-Bova of Endotronics, 313-871-7350/
 (ENDO) CO: Endotronics, Inc. ST: Minnesota IN: MTC SU:


ML -- DE011 -- 7102 02/05/92 10:47 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 5, 1992
Words:270
Previous Article:AMERICAN AIRCRAFT CORP. (NASDAQ: AARC) MANAGEMENT KNOWS OF NO REASON FOR SUDDEN DECLINE IN STOCK
Next Article:PONTIAC GRAND AM IS AUTOMUNDO'S '1992 CAR OF THE YEAR'
Topics:


Related Articles
CELLEX BIOSCIENCES RECEIVES U.S. PATENT ON CELL CULTURE APPARATUS
AASTROM BIOSCIENCES RECEIVES US PATENT FOR DEVICES TO PRODUCE HUMAN CELLS AND TISSUES
Protein Polymer Issued Two More Key U.S. Patents
Ortec Successfully Defends Patent on Re-examination
Advanced Cell announces ruling on human applications of nuclear transfer, issuance of patent, and intent to appeal adverse ruling on animal claims.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters